Eosinophilic myocarditis

Cantargia presents new preclinical data showing unique improvement of heart function in myocarditis using antibody CAN10

Retrieved on: 
Monday, May 10, 2021
Medical specialties, Branches of biology, Heart diseases, Clinical medicine, Interleukins, Myocarditis, Interleukin-1 receptor, Inflammation, Carditis, Eosinophilic myocarditis, Galectin-3

These data demonstrate that the interleukin-1 receptor accessory protein (IL1RAP)-binding antibody CAN10 reduces inflammation and/or fibrosis in several disease models including myocarditis.

Key Points: 
  • These data demonstrate that the interleukin-1 receptor accessory protein (IL1RAP)-binding antibody CAN10 reduces inflammation and/or fibrosis in several disease models including myocarditis.
  • Favorable therapeutic effects were presented using a murine surrogate CAN10 antibody in multiple preclinical models of inflammatory or autoimmune diseases, including myocarditis.
  • In myocarditis, disease development is driven by inflammation and subsequent fibrosis of the myocardium, resulting in deterioration of the cardiac function.
  • CAN10 significantly reduced the development of inflammation and fibrosis in a preclinical model when treatment was given during five weeks after induction of disease.

Rapid Heart Function Analysis by Avalon-H90 Device May Help Identify Myocarditis In Post COVID-19 Patients

Retrieved on: 
Tuesday, October 6, 2020
Heart diseases, Medical specialties, Circulatory system, Cardiovascular system, RTT, Myocarditis, Coronavirus disease, Sudden cardiac death of athletes, Heart failure, Eosinophilic myocarditis, Cardiomyopathy

The use of this technology for heart screening is our main interest and the center of our attention.

Key Points: 
  • The use of this technology for heart screening is our main interest and the center of our attention.
  • According to thearticle published by Ohio State Universityon September 11, 2020 in medical journal JAMA,26 competitive athletes who had COVID-19 had symptoms of myocarditis.
  • Myocarditis affects the heart muscle and can cause heart failure or sudden death.Dr.
  • There is a need for fast, noninvasive and reliable heart screening for all patients who were affected by COVID-19 and potentially developed myocarditis.

AstraZeneca Partners with Actor and Author Tony Hale to Build Awareness of Eosinophilic Asthma and How Not All Asthma is the Same

Retrieved on: 
Tuesday, August 11, 2020
Managed care, Other Health, General Health, Entertainment, Film & Motion Pictures, Pharmaceutical, Books, Oncology, General Entertainment, TV and Radio, Cardiology, Biotechnology, Health, Medical specialties, Branches of biology, Clinical medicine, Asthma, Respiratory therapy, Immune system disorders, Eosinophil, Eosinophilic myocarditis, Reslizumab, Eosinophilic Asthma, AstraZeneca

Visit www.easthma.com to sign up for a free blood test and learn more information about eosinophilic asthma.

Key Points: 
  • Visit www.easthma.com to sign up for a free blood test and learn more information about eosinophilic asthma.
  • *Although not defined by clinical guidelines, eosinophilic asthma was considered an eosinophil count of 150 cells/L or more for this CDC survey analysis.
  • To learn more about eosinophilic asthma and to sign up for a free blood test, visit www.easthma.com .
  • Asthma.

Cantargia Selects CAN10 as Development Project in Systemic Sclerosis and Myocarditis

Retrieved on: 
Thursday, December 5, 2019
Medical specialties, Organ systems, Medicine, Monoclonal antibodies, Heart diseases, Humanized antibody, Systemic scleroderma, Myocarditis, Eosinophilic myocarditis, Monoclonal antibody therapy

The project will focus on unmet medical need in systemic sclerosis and myocarditis.

Key Points: 
  • The project will focus on unmet medical need in systemic sclerosis and myocarditis.
  • The lead project CAN04 is in phase IIa clinical development for the treatment of pancreatic cancer and non-small cell lung cancer.
  • With CAN10, Cantargia now advances two of these fully humanized lead antibodies to the next step of development.
  • Based on this analysis, the initial focus for development will be the two life-threatening diseases systemic sclerosis and myocarditis.

Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society

Retrieved on: 
Tuesday, July 9, 2019
Science, Biotechnology, Other Science, Research, Health, General Health, Branches of biology, Medical specialties, Medicine, Dexpramipexole, Thiazoles, Eosinophil, Immune system disorders, Eosinophilic myocarditis, Hypereosinophilia

The analysis showed that the magnitude of eosinophil lowering by dexpramipexole increased in a stepwise manner in subjects with greater baseline eosinophil counts, with the greatest effect seen in subjects with baseline eosinophilia.

Key Points: 
  • The analysis showed that the magnitude of eosinophil lowering by dexpramipexole increased in a stepwise manner in subjects with greater baseline eosinophil counts, with the greatest effect seen in subjects with baseline eosinophilia.
  • The findings help explain the greater eosinophil lowering seen in previous trials of dexpramipexole in eosinophil-associated diseases relative to ALS.
  • Irrespective of baseline eosinophil count, absolute eosinophil count was lowered to the 0.02-0.03x109/L range, suggesting that dexpramipexole may have minimal effects on non-IL-5-driven homeostatic eosinophil populations.
  • Knopp has reported Phase 2 clinical trial results in HES and CRSwNP and is initiating a Phase 2 trial in severe eosinophilic asthma.